Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881035 | 0.77 | LMNA (0.38) | TSHRLMNA | |
| SCHEMBL5880813 | 0.70 | LMNA (0.33) | TSHRLMNA | |
| SCHEMBL5912277 | 0.69 | LMNA (0.35) | LMNAALDH1A1CYP2C9GAA | |
| SCHEMBL3991120 | 0.68 | LMNA (0.32) | TSHRLMNA | |
| SCHEMBL8117407 | 0.67 | LMNA (0.42) | TSHRLMNA | |
| SCHEMBL3987983 | 0.66 | CTSD (0.32) | TSHRLMNA | |
| SCHEMBL3991115 | 0.66 | LMNA (0.33) | TSHRLMNA | |
| SCHEMBL4298710 | 0.66 | LMNA (0.33) | TSHRLMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8115022 | 0.66 | LMNA (0.41) | TSHRLMNA | |
| SCHEMBL8115140 | 0.63 | APP (0.32) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490350-B1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER (US) | 2006-08-23 | — | — | EP | disclosed |
| US-6878727-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1490350-A1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030195239-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003082848-A1 | PYRANON AND PYRANDION INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE | PFIZER INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195239-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | TSHR 4398/4885LMNA 3489/4885ALDH1A1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.